Guardant Health Inc
GH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$81.00 | Ythfw | Ngbrvtgs |
Guardant Health Earnings: Momentum Continues in Therapy Selection Liquid Biopsies
Guardant Health delivered strong first-quarter results, and management increased its sales outlook for the full year. Our 2023 assumptions remain within the company's new guidance range, and we do not anticipate changing our $63 fair value estimate at first glance. Also, although our moat rating remains no-moat, we are still optimistic about Guardant's liquid biopsy pipeline, particularly for early detection of colorectal cancer, which is reflected in our positive moat trend rating.